Article

Lung Cancer Breath Test Might Soon Be Reality

Researchers at the University of Leicester and Leicester's Hospitals are evaluating a revolutionary device which detects lung cancer in early stages.

A clinical trial led by University of Leicester respiratory experts into a potentially ground-breaking "breath test" to detect lung cancer is set to get underway at the Glenfield Hospital in Leicester.

It is hoped that the LuCID (Lung Cancer Indicator Detection) programme will lead to a non-invasive method of diagnosing lung cancer in the early stages. The company behind the device, Cambridge-based Owlstone Nanotech Ltd, carried out a health economic analysis and determined that detection of early-stage lung cancer could be increased from the current 14.5% to 25% by 2020, it is estimated this could save 10,000 lives and £250 million (approximately $384,537,500) of National Health Service money. A clinical trial led by University of Leicester respiratory experts into a potentially ground-breaking 'breath test' to detect lung cancer is set to get underway at the Glenfield Hospital in Leicester.

Link to the complete article on MedicalXpress: http://bit.ly/1DxHzXE

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
Coral Omene, MD, PhD, sitting for a vieo interview
Constance Blunt, MD, medical oncologist, Mary Bird Perkins Cancer Center
Coral Omene, MD, PhD, sitting for a vieo interview
David Awad, PharmD, BCOP
Screenshot of Coral Omene, MD, PhD
ASCO 2025
Constance Blunt, MD, medical oncologist, Mary Bird Perkins Cancer Center
Cathy Eng, MD, FACP, FASCO
Nini Wu, MD, Navista
Eileen Peng, PharmD, sitting for a video interview
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo